Frontier's FMC-376 achieved a 56% response rate in 18 evaluable lung cancer patients, including prior KRAS inhibitor users. Can larger trials confirm benefit?
Genialis reports improved cancer response prediction using small patient cohorts and longitudinal AI analysis. Clinical validation remains the next hurdle.
Frontier Medicines will present its first Phase 1 clinical findings for FMC-376 at ESMO 2026, including preliminary responses in patients previously treated with KRAS G12C inhibitors. The investigational drug targets both active and inactive KRAS G12C, but detailed response rates and patient counts remain undisclosed ahead of the presentation.
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.